Regentis Biomaterials Ltd. RGNT
1.98
(0.06)
(2.94%)
as of 25 Sep
- Market cap
- $15.8M
- P/E
- —
Follow RGNT
| Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|
Current Ratio |
0.11 | 0.07 | 2.65 |
Net Debt/EBITDA |
(3.76) | 5.06 | 0.89 |
Debt/Assets |
2,115.28% | 1,025.93% | 15.71% |
Debt/Equity |
(0.17) | (0.12) | 0.25 |
Asset Turnover |
— | 0.00 | 0.00 |
Operating CF/Net income |
0.29 | (0.13) | 0.10 |
Interest Coverage |
0.00 | 0.00 | 0.00 |
| 0.00% | (10.93%) | 75.31% | |
| 0.00% | 1,128.98% | (338.07%) | |
ROIC |
0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
150.41% | (79.14%) | (288.62%) |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% |
Free Cash Flow per Share |
(7.03) | (0.23) | (2.43) |
Cash per Share |
1.99 | 0.08 | 13.02 |
Shareholders Equity per Share |
(264.58) | (14.86) | 8.37 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
(264.58) | (14.86) | 8.37 |
Free Cash Flow |
(1.22) | (0.64) | (1.37) |
Working Capital |
(2.78) | (6.01) | 4.74 |
Net Current Asset Value |
(45.90) | (41.10) | 4.74 |
| Other line items | |||
Quick Ratio |
0.11 | 0.04 | 2.57 |
Cash ROIC |
3.22% | 1.78% | (10.32%) |
Accounts Payable Turnover |
— | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 |
Operating CF per Share |
(7.03) | (0.23) | (2.43) |
Capex per Share |
0.00 | 0.00 | 0.00 |
Average Payables |
— | 0.30 | 0.26 |
Average Assets |
— | 0.42 | 4.05 |
Average Common Equity |
— | (43.50) | (18.18) |
Net Profit Margin |
0.00% | 0.00% | 0.00% |
Columns are period end dates